Studies have shown that BA can activate or suppress the FXR and well known for the treatment of metabolic disorder 71 Overexpression studies with hepatic FATP5 have shown that they not only enhance the LCFA uptake 53 but also activates the primary bile precursors 72. The gene discussed is NR1H4; the disease is Other metabolic disease.